Filing Flows › Comparisons › CTMX vs PMHS
CytomX Therapeutics vs Polomar Health Services: CTMX and PMHS compared
CytomX Therapeutics is the larger company: $1.7M of revenue in its latest quarter (Q3 2026) against $1.5M for Polomar Health Services (Q2 2026). Polomar Health Services is growing faster (279× against -72% a year earlier).
Where the money goes: CTMX and PMHS
CytomX Therapeutics (CTMX) · Q3 2026
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.
Polomar Health Services (PMHS) · Q2 2026
Polomar Health Services, Q2 2026: revenue $1.5M (279× year over year), operating margin 14.3%, net earnings $200K, operating cash flow $121K. The chart follows the revenue to costs, profit and cash.
| CytomX Therapeutics (CTMX) | Polomar Health Services (PMHS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $1.7M | $1.5M |
| Revenue growth, Y/Y | -72% | 279× |
| Gross margin | — | 61.2% |
| Operating margin | n/m | 14.3% |
| Net earnings | −$20.0M | $200K |
| Net margin | — | 13.1% |
| Operating cash flow | $16.6M | $121K |
| Free cash flow | $16.1M | — |
Questions
Which is bigger, CytomX Therapeutics or Polomar Health Services?
CytomX Therapeutics is the larger company: $1.7M of revenue in its latest quarter (Q3 2026) against $1.5M for Polomar Health Services (Q2 2026).
Is CytomX Therapeutics or Polomar Health Services growing faster?
Polomar Health Services is growing faster (279× against -72% a year earlier).
More: CytomX Therapeutics earnings · how CytomX Therapeutics makes money · Polomar Health Services earnings · how Polomar Health Services makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.